Receive our newsletter – data, insights and analysis delivered to you
July 6, 2009

EU Commission Approves Viramune

The European Commission has approved Boehringer Ingelheim's update of Viramune (nevirapine) for the treatment of patients with HIV. The EU commission approved an update of the Summary of Product Characteristics (SPC) for Viramune, which reflect clinical studies demonstrating that nevirapi

By cms admin

The European Commission has approved Boehringer Ingelheim’s update of Viramune (nevirapine) for the treatment of patients with HIV.

The EU commission approved an update of the Summary of Product Characteristics (SPC) for Viramune, which reflect clinical studies demonstrating that nevirapine has been associated with an increase in HDL cholesterol and an overall improvement in the total HDL cholesterol ratio.

Boehringer Ingelheim senior vice-president of medicine Dr Manfred Haehl said that the company was pleased that Viramune’s positive impact on lipids had been recognised by the European Commission.

“Cardiovascular disease has become an increasing cause of morbidity and mortality in patients with HIV. Physicians treating patients with HIV need to have a range of treatment options available so they can tailor the therapy to the individual patient’s need and response,” Haehl said.

“We are further exploring Viramune’s effect on lipid profiles and hope to provide further insights with the upcoming ARTEN study.”

The decision followed a positive recommendation by the Committee for Medical Products for Human Use (CHMP) and the scientific committee of the European Medicines Agency (EMEA).

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU